By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gilead Sciences Ltd. 

2 Roundwood Avenue
South Building - Stockley Park
Uxbridge  Middlesex  UB11 1AZ  United Kingdom
Phone: 44-0-208-587-2200 Fax: 44-0-208-744-6773


Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Kristen Metza, Senior Vice President, Human Resources
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Senior Director, Public Affairs

Key Statistics

Ownership: Public

Web Site: Gilead Sciences Ltd.
Employees: 3,200
Symbol: GILD

Company News
Roy D. Baynes, MD, PhD, to Join Gilead Sciences Ltd. (GILD) as Senior Vice President, Oncology Therapeutics Network 1/19/2012 6:19:58 AM
Gilead Sciences Ltd. (GILD) Completes Acquisition of Pharmasset, Inc. (VRUS) 1/18/2012 5:58:07 AM
AHF Slams Gilead Sciences Ltd. (GILD) “HIV Prevention Pill” FDA Application 12/16/2011 9:37:56 AM
Gilead Sciences Ltd. (GILD) Seeks First-ever Approval for Drug to Prevent HIV 12/16/2011 7:13:17 AM
AHF Salutes on Gilead Sciences Ltd. (GILD) on Price Cuts for US AIDS Drug Program 12/6/2011 7:43:32 AM
Gilead Sciences Ltd. (GILD) to Present at the 2011 Credit Suisse Healthcare Conference on Wednesday, November 9 11/9/2011 6:43:09 AM
Gilead Sciences Ltd. (GILD) Submits NDA to FDA for Quad Tablet 10/28/2011 7:10:33 AM
Gilead Sciences Ltd. (GILD) and GlobeImmune, Inc. Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection 10/25/2011 9:07:48 AM
Gilead Sciences Ltd. (GILD) Announces Second Quarter 2011 Financial Results 7/27/2011 8:13:49 AM
Gilead Sciences Ltd. (GILD) to Present at the 31st Annual William Blair & Company Growth Stock Conference on Wednesday, June 15 6/9/2011 9:33:26 AM